Gene delivery to in situ veins: Differential effects of adenovirus and adeno-associated viral vectors

Journal of Vascular Surgery

Volumn 31, Issue 6, 2000, Pages 1149-1159

  Eslami, Mohammad H ^a   Gangadharan, Sidhu P ^a   Sui, XinXin ^a   Rhynhart, Kurt K ^a   Snyder, Richard O ^a   Conte, Michael S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; GREEN FLUORESCENT PROTEIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE TARGETING; GENE THERAPY; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VEIN GRAFT; VIRUS EXPRESSION;

EID: 0033918477     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva2000.106951     Document Type: Article

References (54)

1. Campeau L, Enjalbert M, Lesperance J, et al. Atherosclerosis and the late closure of aortocoronary saphenous vein grafts: sequential studies at 2 weeks, 1 year, 5-7 years, and 10-12 years after surgery. Circulation 1985;68(Suppl II):1-7.
2. Virmani R, Atkinson JB, Forman MB. Aortocoronary saphenous vein bypass grafts. Cardiovasc Clin 1988;18:41-59.
3. Whittemore AD. Infrainguinal bypass. In: Rutherford R, editor. Vascular surgery. Philadelphia: WB Sanders; 1995. p. 794-814
4. Harris RW, Andros G, Dulawa LB, et al. Successful longterm limb salvage using cephalic vein bypass grafts. Ann Surgery 1984;200:785-92.
5. Londrey GL, Bosher P, Brown PW, et al. Infrainguinal reconstruction with arm vein, lesser saphenous vein, and remnants of greater saphenous vein: a report of 257 cases. J Vasc Surg 1994;20:451-7.
6. Belkin M, Conte MS, Donaldson MC, Mannick JA, Whittemore AD. Preferred strategies for secondary infrainguinal bypass surgery: lessons learned from 300 consecutive re-operations. J Vasc Surg 1995;21(2)282-95.
7. Conte MS. The ideal small arterial substitute: A search for the Holy Grail? FASEB J 1997;12:43-5.
8. Nabel EG, Pompili VJ, Plautz GE, Nabel GJ. Gene transfer and vascular disease. Cardiovasc Res 1994;18:445-55.
9. Mann MJ, Conte MS. Gene therapy for vascular disease. In: Whittemore AD, editor. Advances in vascular surgery. Volume 6. St. Louis: Mosby; 1998. p. 239-67.
10. Lemarchand P, Jones M, Yamada I, et al. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993;72:1132-8.
11. Newman KD, Dunn PF, Owens JW, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation and neointimal hyperplasia. J Clin Invest 1995;96:2955-65.
12. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virology 1996;8098-108.
13. Snyder RO, Spratt SK, Lagarde C, et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997;8:1891-1900.
14. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998;72:4212-23.
15. Guy J, Qi X, Muzyczka N, Hauswirth WW. Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthamol 1999;117:929-37.
16. Snyder RO, Xiao X, Samulski, RJ. Production of recombinant adeno-associated viral vectors. In: Dracopoli N, editor. Current protocols in human genetics. Volume 1. New York: John Wiley and Sons; 1996.
17. Graham FL, Prevec L. Methods in molecular biology. Volume 7: Gene transfer and expression protocols. Clifton, NJ: Humana Press; 1991. p. 109-28.
18. McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol 1988;62:1963-73.
19. Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer Proc Natl Acad Sci U S A 1987;84:156-60.
20. 3 monoclonal antibody 7E3 and its involvement in leukocyte adherence. J Biol Chem 1998;273(32):20372-7.
21. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991;251:788-91.
22. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996;70:3227-34.
23. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann NY Acad Sci 1994;716:90-101.
24. Lee SW, Trapnell BC, Rade JJ, et al. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993;73:797-807.
25. Guzman RJ, Lemarchand P, Crystal RG, et al. Efficient and selective adenovirus-mediated gene transfer into vascular neo-intima. Circulation 1993;88:2838-48.
26. Kozarsky KF, Wilson JM. Gene therapy: Adenovirus vectors. Curr Opin Genet Dev 1993;3:499-503.
27. Schulick AH, Vassali G, Dunn PF, et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. J Clin Invest 1997;99:209-19.
28. Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries: optimization and evaluation of acute toxicity. Circulation 1995;91:2407-14.
29. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenovirus defective in E2a. Hum Gene Ther 1994;5:1217-29.
30. Wilmott RW, Amin RS, Perez CR, et al. Safety of adenovirus-mediated transfer to the human cystic fibrosis transmembrane conductance regulator cDNA to the lung of non-human primates. Hum Gene Ther 1996;7:310-8.
31. Yang Y, Li Q, Ertl HCJ, et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed therapy with recombinant adenoviruses. J Virol 1995;69:2004-15.
32. Yang Y, Nunnes FA, Berencsi K, et al. Cellular immunity to viral gene limits El-deleted adenovirus for gene therapy. Proc Natl Acad Sci U S A 1994;91:4407-11.
33. Yang Y, Ertl HCJ, Wilson JM. MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenovirus. Immunity 1994;1:433-42.
34. Roesseler BJ, Allen ED, Wilson JM, et al. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993;92:1085-92.
35. Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s. Nature 1993;362:801-9.
36. Hoch JR, Stark VK, Hullett DA, Turnipseed WD. Vein graft intimal hyperplasia: leukocytes and cytokine gene expression. Surgery 1994;116:463-71.
37. Stark VK, Hoch JR, Warner TF, Hullett DA. Monocyte chemoattractant protein-1 expression is associated with the development of vein graft intimai hyperplasia. Arterioscler Thromb Vasc Biol 1997;17:1614-21.
38. Schwartz LB, Moawad J, Svensson EC, et al. Adenovirus-mediated gene transfer of constitutively active form of the retinoblastoma gene product attenuates neointimal thickening inexperimental vein grafts. J Vasc Surg 1999;29:874-83.
39. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of adeno-associated virus 2 genome. J Virol 1983;45:555-64.
40. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965;194:754-6.
41. Snyder RO. Adeno-associated virus-mediated gene delivery. J Genet Med 1999;1:1-17.
42. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Microbiol Immunol 1992;158:98-129.
43. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentration of human factor IX in mice after hepatic gene transfer of recombinant AAV vector. Nat Genet 1997;16:270-6.
44. Lynch CM, Hara PS, Leonard JC, et al. Adeno-associated virus vector for vascular gene delivery. Circ Res 1997;80:497-505.
45. Maeda Y, Ikeda U, Ogasawara Y, et al. Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. Cardiovasc Res 1997;35:514-21.
46. Gnatenko D, Arnold TE, Zolotukhin S, et al. Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells. J Invest Med 1997;45:87-98.
47. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998;72:1438-45.
48. Qing K, Mah C, Hansen J, et al. Human fibroblast growth factor receptor I is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999;5:71-7.
49. Summerford C, Bartlettt JS, Samulski RJ. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 1999;5:78-82.
50. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentration of human factor IX in mice after hepatic gene transfer of recombinant AAV vector. Nat Genet 1997;16:270-6.
51. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999;5:64-70.
52. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated vein. J Virol 1996;70:3227-34.
53. Fisher KJ, Joos K, Altson J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3:306-12.
54. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Nad Cancer Inst 1968;40:319-27.